Rep. Jefferson Shreve Sells Off Shares of Becton, Dickinson and Company (NYSE:BDX)

Representative Jefferson Shreve (R-Indiana) recently sold shares of Becton, Dickinson and Company NYSE: BDX. In a filing disclosed on April 11th, the Representative disclosed that they had sold between $15,001 and $50,000 in Becton, Dickinson and Company stock on March 5th. The trade occurred in the Representative's "CRT - STANDARD UNIT TRUST" account.Intuitive Surgical Gives Buying Opportunity Off Its 52 Week HighsRepresentative Jefferson Shreve also recently made the following trade(s): Purchased $15,001 - $50,000 in shares of Harley-Davidson NYSE: HOG on 3/31/2025. Purchased $50,001 - $100,000 in shares of Block NYSE: XYZ on 3/31/2025. Sold $15,001 - $50,000 in shares of DuPont de Nemours NYSE: DD on 3/31/2025. Purchased $15,001 - $50,000 in shares of United Community Banks NASDAQ: UCB on 3/31/2025. Sold $15,001 - $50,000 in shares of IDEX NYSE: IEX on 3/31/2025. Purchased $15,001 - $50,000 in shares of HNI NYSE: HNI on 3/31/2025. Sold $50,001 - $100,000 in shares of ServiceNow NYSE: NOW on 3/31/2025. Sold $15,001 - $50,000 in shares of Coinbase Global NASDAQ: COIN on 3/31/2025. Sold $15,001 - $50,000 in shares of Constellation Energy NASDAQ: CEG on 3/31/2025. Sold $50,001 - $100,000 in shares of Simon Property Group NYSE: SPG on 3/31/2025. Becton, Dickinson and Company Trading Up 1.9 %NYSE BDX opened at $205.65 on Tuesday. The company has a quick ratio of 0.63, a current ratio of 1.13 and a debt-to-equity ratio of 0.69. The stock has a market capitalization of $59.05 billion, a P/E ratio of 34.16, a P/E/G ratio of 1.63 and a beta of 0.35. Becton, Dickinson and Company has a 52-week low of $193.03 and a 52-week high of $251.99. The firm has a 50-day moving average price of $223.18 and a 200 day moving average price of $229.56. Healthcare Stocks With at Least 30 Years of Dividend IncreasesBecton, Dickinson and Company (NYSE:BDX - Get Free Report) last issued its earnings results on Wednesday, February 5th. The medical instruments supplier reported $3.43 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $3.00 by $0.43. Becton, Dickinson and Company had a net margin of 8.47% and a return on equity of 15.74%. Equities research analysts expect that Becton, Dickinson and Company will post 14.43 EPS for the current year. Becton, Dickinson and Company Dividend AnnouncementThe business also recently disclosed a quarterly dividend, which was paid on Monday, March 31st. Shareholders of record on Monday, March 10th were paid a dividend of $1.04 per share. This represents a $4.16 annualized dividend and a yield of 2.02%. The ex-dividend date of this dividend was Monday, March 10th. Becton, Dickinson and Company's dividend payout ratio is presently 69.10%. Becton, Dickinson and Company announced that its Board of Directors has authorized a stock buyback plan on Tuesday, January 28th that permits the company to repurchase 10,000,000 outstanding shares. This repurchase authorization permits the medical instruments supplier to buy shares of its stock through open market purchases. Shares repurchase plans are typically an indication that the company's leadership believes its shares are undervalued. Insider Buying and SellingIn related news, EVP Michael David Garrison sold 597 shares of the firm's stock in a transaction that occurred on Friday, January 17th. The shares were sold at an average price of $236.51, for a total transaction of $141,196.47. Following the completion of the sale, the executive vice president now directly owns 5,544 shares in the company, valued at approximately $1,311,211.44. This trade represents a 9.72 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, EVP Richard Byrd sold 1,940 shares of the company's stock in a transaction on Wednesday, March 12th. The shares were sold at an average price of $224.91, for a total value of $436,325.40. Following the completion of the transaction, the executive vice president now directly owns 7,411 shares in the company, valued at $1,666,808.01. This represents a 20.75 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 4,675 shares of company stock valued at $1,057,182 over the last quarter. Corporate insiders own 0.36% of the company's stock. Institutional Investors Weigh In On Becton, Dickinson and CompanyA number of institutional investors have recently modified their holdings of BDX. Bank of Jackson Hole Trust acquired a new position in Becton, Dickinson and Company during the 4th quarter valued at about $25,000. REAP Financial Group LLC lifted its holdings in Becton, Dickinson and Company by 75.3% in the fourth quarter. REAP Financial Group LLC now owns 128 shares of the medical instruments supplier's stock worth $29,000 after purchasing an additional 55 shares during the period. Sierra Ocean LLC acquired a new position in Becton, Dickinson and Company during the 4th quarter valued at about $29,000. Picton Mahoney Asset Management lifted its stake in shares of Becton, Dickinson and Company by 61.4% in the 4th quarter. Picton Mahoney Asset Management now owns 142 shares of the medical instruments supplier's stock worth $32,000 after acquiring an additional 54 shares during the period. Finally, Nexus Investment Management ULC bought a new position in shares of Becton, Dickinson and Company in the first quarter valued at approximately $34,000. Institutional investors own 86.97% of the company's stock. Analyst Ratings ChangesSeveral equities research analysts have commented on the company. StockNews.com upgraded Becton, Dickinson and Company from a "hold" rating to a "buy" rating in a research note on Wednesday, April 2nd. Piper Sandler boosted their price objective on Becton, Dickinson and Company from $275.00 to $280.00 and gave the stock an "overweight" rating in a research note on Tuesday, January 28th. Finally, Barclays reduced their price target on Becton, Dickinson and Company from $279.00 to $261.00 and set an "overweight" rating on the stock in a research report on Monday, April 7th. Eight equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company has a consensus rating of "Buy" and an average price target of $275.71.View Our Latest Stock Report on BDXAbout Representative ShreveJefferson Shreve (Republican Party) is a member of the U.S. House, representing Indiana's 6th Congressional District. He assumed office on January 3, 2025. His current term ends on January 3, 2027. Shreve (Republican Party) is running for re-election to the U.S. House to represent Indiana's 6th Congressional District. He declared candidacy for the 2026 election. Email editor@ballotpedia.org to notify us of updates to this biography. Jefferson Shreve earned a bachelor's degree from Indiana University in 1989, a graduate degree from the University of London in 1998, and a graduate degree from Purdue University in 2003. Shreve's career experience includes working as a real estate executive. Shreve was elected 7th District Vice Chairman of the Indiana Republican State Committee on January 17, 2018, and was re-elected on March 6, 2021. In 2020, he was selected as a district-level delegate to the 2020 Republican National Convention.Becton, Dickinson and Company Company Profile (Get Free Report)Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.See AlsoFive stocks we like better than Becton, Dickinson and Company3 Small Caps With Big Return Potential3 ETFs Thriving in April’s Market Chaos—Are You Missing Out?How Technical Indicators Can Help You Find Oversold Stocks Financial Sector: Pullback Opportunity or Warning Sign?What is the Dow Jones Industrial Average (DJIA)?Traders Started Betting on PayPal's Rally AgainThis instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.Should You Invest $1,000 in Becton, Dickinson and Company Right Now?Before you consider Becton, Dickinson and Company, you'll want to hear this.MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Becton, Dickinson and Company wasn't on the list.While Becton, Dickinson and Company currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.View The Five Stocks Here